# To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP

> **NCT05581199** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Immunovant Sciences GmbH** · enrollment: 277 (estimated)

## Conditions studied

- Chronic Inflammatory Demyelinating Polyneuropathy

## Interventions

- **DRUG:** Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly
- **DRUG:** Batoclimab 340 mg SC weekly
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05581199
- **Lead sponsor:** Immunovant Sciences GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-15
- **Primary completion:** 2026-01
- **Final completion:** 2027-01
- **Target enrollment:** 277 (ESTIMATED)
- **Last updated:** 2024-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05581199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05581199, "To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05581199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*